Related Experiment Video

Updated: Dec 6, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.2K

CURING HEPATITIS C WITH THE NEW DIRECT ACTING ANTIVIRALS DID NOT IMPROVE INSULIN RESISTANCE AFTER ONE YEAR

Lohanna Strauhs-Nitsch1, Marcela Ferro Campiolo1, Daphne Benatti Gonçalves Morsoletto1

  • 1Hospital Nossa Senhora das Graças, Departamento de Gastroenterologia e Hepatologia, Curitiba, PR, Brasil.

Arquivos De Gastroenterologia
|October 7, 2020
PubMed

Insights

Direct-acting agents (DAA) for hepatitis C did not significantly alter insulin resistance (IR) levels, despite initial weight gain post-treatment. Further research is needed to understand long-term metabolic impacts.

Area of Science:

  • Hepatology
  • Metabolic Syndrome
  • Virology

Background:

  • Chronic hepatitis C is a significant health issue in Brazil, linked to metabolic disturbances like insulin resistance (IR).
  • IR can negatively impact treatment outcomes and disease progression in hepatitis C patients.
  • Direct-acting agents (DAA) represent a new treatment modality, necessitating evaluation of their effect on IR.

Purpose of the Study:

  • To compare Homeostatic Model Assessment for IR (HOMA-IR) scores in chronic hepatitis C patients before and 12 months after DAA treatment with sustained virologic response (SVR).
  • To assess weight changes in patients following successful hepatitis C cure with DAA therapy.

Main Methods:

  • A cohort of 75 adult patients with chronic hepatitis C receiving DAA treatment was studied.
  • Fasting insulin, glucose, and glycated hemoglobin were measured pre-treatment and 12 months post-SVR.
  • IR was calculated using HOMA-IR, with IR defined as HOMA-IR > 2.5. Epidemiological and clinical data were also collected.

Main Results:

  • Before DAA treatment, 41.3% of patients had IR; this increased to 52% at 12 months post-SVR.
  • No statistically significant differences were observed in insulin, glucose, or HOMA-IR levels before and after treatment.
  • A transient weight gain was noted post-cure, but it was not sustained at the 12-month follow-up.

Conclusions:

  • DAA treatment for hepatitis C did not result in a statistically significant change in HOMA-IR scores 12 months after achieving SVR.
  • Weight gain observed after hepatitis C cure was not statistically significant at the one-year follow-up mark.
Abstract

More Related Videos

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.7K
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

10.7K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
48.8K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
498
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
425
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
523
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
125
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
103